Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Making Its Mark in Global Biopharma Patent Filings

publication date: Jun 10, 2015
Innovation is on the rise in China's Biotech and Pharma sectors, according to a survey of patent filings and patent approvals conducted by Thomson Reuters. Of all the institutions/ companies filing patents globally in 2014, China is home to three of the top five Biotech filing institutions and two of the top five Pharma filing entities. Globally, the number of filings/approvals climbed just 3% last year in all sectors. The Biotech and Pharma sectors, however, are much stronger than the overall average, and the difference seems to have been China's rising contribution. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here